EVAX vs. INAB, ENTX, PLUR, NSTG, AIM, ELEV, FRLN, SRNE, APTO, and CRTX
Should you be buying Evaxion Biotech A/S stock or one of its competitors? The main competitors of Evaxion Biotech A/S include IN8bio (INAB), Entera Bio (ENTX), Pluri (PLUR), NanoString Technologies (NSTG), AIM ImmunoTech (AIM), Elevation Oncology (ELEV), Freeline Therapeutics (FRLN), Sorrento Therapeutics (SRNE), Aptose Biosciences (APTO), and Cortexyme (CRTX). These companies are all part of the "medical" sector.
Evaxion Biotech A/S (NASDAQ:EVAX) and IN8bio (NASDAQ:INAB) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, dividends, profitability, institutional ownership, community ranking, risk and valuation.
Evaxion Biotech A/S has a beta of 0.35, meaning that its stock price is 65% less volatile than the S&P 500. Comparatively, IN8bio has a beta of -0.22, meaning that its stock price is 122% less volatile than the S&P 500.
Evaxion Biotech A/S currently has a consensus price target of $7.00, indicating a potential upside of 797.44%. IN8bio has a consensus price target of $11.00, indicating a potential upside of 1,220.85%. Given IN8bio's higher probable upside, analysts plainly believe IN8bio is more favorable than Evaxion Biotech A/S.
Evaxion Biotech A/S is trading at a lower price-to-earnings ratio than IN8bio, indicating that it is currently the more affordable of the two stocks.
0.6% of Evaxion Biotech A/S shares are owned by institutional investors. Comparatively, 7.4% of IN8bio shares are owned by institutional investors. 41.6% of Evaxion Biotech A/S shares are owned by company insiders. Comparatively, 33.0% of IN8bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
IN8bio received 3 more outperform votes than Evaxion Biotech A/S when rated by MarketBeat users. Likewise, 64.00% of users gave IN8bio an outperform vote while only 52.00% of users gave Evaxion Biotech A/S an outperform vote.
In the previous week, IN8bio had 1 more articles in the media than Evaxion Biotech A/S. MarketBeat recorded 4 mentions for IN8bio and 3 mentions for Evaxion Biotech A/S. Evaxion Biotech A/S's average media sentiment score of 1.08 beat IN8bio's score of 0.85 indicating that Evaxion Biotech A/S is being referred to more favorably in the media.
IN8bio's return on equity of -152.81% beat Evaxion Biotech A/S's return on equity.
Summary
IN8bio beats Evaxion Biotech A/S on 9 of the 14 factors compared between the two stocks.
Get Evaxion Biotech A/S News Delivered to You Automatically
Sign up to receive the latest news and ratings for EVAX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EVAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Evaxion Biotech A/S Competitors List
Related Companies and Tools
